Skip to main content
. Author manuscript; available in PMC: 2012 Feb 18.
Published in final edited form as: Oncogene. 2011 Mar 21;30(33):3563–3569. doi: 10.1038/onc.2011.76

Figure 1. Tamoxifen treatment resulted in enhanced recruitment of HEXIM1 and inhibition of the recruitment of cyclin T1 and RNAP II to an ER responsive gene.

Figure 1

A. MCF-7 cells were treated with 100 nM E2 or 1 uM TOT for 90 minutes and processed for ChIP assays. ChIP assays were performed with antibodies against HEXIM1 or nonspecific rabbit IgG (as a control for immunoprecipitation). Panel on the left, DNA fragments were analyzed by PCR using primers specific for the promoter region of pS2. Panel on the right, Quantifications of HEXIM1 enrichment at the pS2 promoter. Columns represent the mean of three replicates; bars, SE. *, P < 0.05. B. ChIP assays were performed with antibodies against cyclin T1 or non-specific rabbit IgG (as a control for immunoprecipitation). Panel on the left, DNA fragments were analyzed by PCR using primers specific for the coding region of pS2. Panel on the right, Quantifications of cyclin T1 enrichment at the pS2 promoter or coding regions. Each column represent the mean of three replicates; bars, SE. *, P < 0.05. C. Samples were processed for ChIP assays using antibodies against serine 2 phosphorylated RNAP II. Panel on the left, DNA fragments were analyzed by PCR using primers specific for coding region of pS2. Panel on the right, Quantifications of RNAP II enrichment at the pS2 coding region. Columns represent the mean of three replicates; bars, SE. *, P < 0.05.